Back to mobile site

Baird on Lexeo Therapeutics (LXEO): 'Incrementally positive on deal'

September 22, 2026 9:42 AM EDT Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $28.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).The analyst comments "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login